Answers are grounded in this paper and cite their sources.
Purpose To compare the performance of four published fructosamine-to-HbA1c conversion formulas against continuous glucose monitoring (CGM) data in patients undergoing preoperative diabetes optimization. Methods This retrospective, cross-sectional study included 30 patients enrolled in a preoperative diabetes optimization program who had both fructosamine values and at least 14 days of overlapping CGM data. Four previously published conversion formulas (Cohen, Wright-Hirsch, Kang, and Young) were evaluated. Pearson correlation analysis examined relationships between fructosamine-derived estimated HbA1c values and CGM-derived glucose management indicator (GMI). Results Mean fructosamine was 331.2 ± 70.6 µmol/L, mean CGM glucose was 165.8 ± 34.4 mg/dL, and mean GMI was 7.28% ± 0.82%. Fructosamine demonstrated significant positive correlation with average CGM glucose (r = 0.39, p = 0.04). All four conversion formulas showed similar, statistically significant correlations with GMI (r ≈ 0.39, p ≈ 0.03). Conclusions All four fructosamine conversion formulas demonstrated comparable performance when validated against CGM data in the preoperative setting. These findings support the clinical utility of fructosamine for short-term glycemic assessment when HbA1c may be unreliable or when recent glycemic changes are clinically relevant, in absence of or when unable to use CGM.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: